LILRB1 and renal cell carcinoma: A recent study focused on tumor-infiltrating CD8+ T cells that express the HLA-G receptor ILT2 in renal-cell carcinoma (RCC), and the results emphasize the potential of therapeutically targeting the HLA-G/ILT2 checkpoint in HLA-G+ tumors (127).